Epizyme Executives
EPZMDelisted Stock | USD 1.47 0.00 0.00% |
Epizyme employs about 250 people. The company is managed by 25 executives with a total tenure of roughly 209 years, averaging almost 8.0 years of service per executive, having 10.0 employees per reported executive. Analysis of Epizyme's management performance can provide insight into the firm performance.
Robert Bazemore CEO CEO and President and Director |
Robert Gould CEO CEO and President Secretary and Director |
Epizyme |
Epizyme Management Team Effectiveness
The company has return on total asset (ROA) of (38.96) % which means that it has lost $38.96 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (352.37) %, meaning that it created substantial loss on money invested by shareholders. Epizyme's management efficiency ratios could be used to measure how well Epizyme manages its routine affairs as well as how well it operates its assets and liabilities.Epizyme Workforce Comparison
Epizyme is one of the top stocks in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 83,376. Epizyme adds roughly 250 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
Epizyme Notable Stakeholders
An Epizyme stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Epizyme often face trade-offs trying to please all of them. Epizyme's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Epizyme's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert Bazemore | CEO and President and Director | Profile | |
Robert Gould | CEO and President Secretary and Director | Profile | |
Michael Shih | Vice President - Business Development | Profile | |
Pamela Strode | Vice President - Regulatory Affairs and Quality Assurance | Profile | |
Michael Boretti | Vice President - Business Development | Profile | |
Jason Fredette | Vice President of Investor Relations | Profile | |
Robert Copeland | President of Research and Chief Scientific Officer | Profile | |
Suzanne Fleming | Senior Vice President - Finance, Principal Accounting Officer, Treasurer | Profile | |
Paolo Tombesi | CFO | Profile | |
Andrew Singer | CFO, Executive VP of Fin. and Admin. and Treasurer | Profile | |
Matthew Ros | COO | Profile | |
Richard Pops | Independent Director | Profile | |
Kevin Conroy | Director | Profile | |
Andrew Allen | Director | Profile | |
Stephen Garbacz | Principal Accounting Officer and Executive Director of Fin. | Profile | |
Michael Giordano | Director | Profile | |
Carl Goldfischer | Independent Director | Profile | |
Kenneth Bate | Independent Director | Profile | |
Beth Seidenberg | Independent Director | Profile | |
David Mott | Independent Director | Profile | |
Joseph Beaulieu | Principal Accounting Officer, Controller | Profile | |
Manisha Pai | IR Contact Officer | Profile | |
Shefali Agarwal | Chief Medical Officer | Profile | |
Susan Graf | Chief Business Officer | Profile | |
Peter Ho | Chief Development Officer | Profile |
About Epizyme Management Performance
The success or failure of an entity such as Epizyme often depends on how effective the management is. Epizyme management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Epizyme management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Epizyme management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Epizyme operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 250 people.
The data published in Epizyme's official financial statements usually reflect Epizyme's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Epizyme. For example, before you start analyzing numbers published by Epizyme accountants, it's critical to develop an understanding of what Epizyme's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Epizyme's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Epizyme's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Epizyme's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Epizyme. Please utilize our Beneish M Score to check the likelihood of Epizyme's management manipulating its earnings.
Epizyme Workforce Analysis
Traditionally, organizations such as Epizyme use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Epizyme within its industry.Epizyme Manpower Efficiency
Return on Epizyme Manpower
Revenue Per Employee | 154K | |
Revenue Per Executive | 1.5M | |
Net Loss Per Employee | 945.4K | |
Net Loss Per Executive | 9.5M | |
Working Capital Per Employee | 778.5K | |
Working Capital Per Executive | 7.8M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Epizyme information on this page should be used as a complementary analysis to other Epizyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Epizyme Stock
If you are still planning to invest in Epizyme check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Epizyme's history and understand the potential risks before investing.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
CEOs Directory Screen CEOs from public companies around the world | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Global Correlations Find global opportunities by holding instruments from different markets |